Exicure (NASDAQ:XCUR) Issues Earnings Results

Exicure (NASDAQ:XCUR) announced its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.14, FiscalAI reports.

Exicure Price Performance

Shares of NASDAQ:XCUR opened at $4.49 on Thursday. Exicure has a 1 year low of $3.10 and a 1 year high of $14.73. The stock has a market capitalization of $28.60 million, a price-to-earnings ratio of -1.21 and a beta of 4.13. The company’s 50 day simple moving average is $4.41 and its 200 day simple moving average is $4.66.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Exicure in a report on Monday, December 29th. Wall Street Zen raised Exicure to a “hold” rating in a research note on Saturday, January 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.